AAPL   395.61 (+3.11%)
MSFT   214.48 (+0.38%)
FB   247.24 (+0.89%)
GOOGL   1,562.67 (+1.54%)
AMZN   3,274.31 (+2.32%)
NVDA   421.63 (+0.59%)
CGC   17.99 (+3.27%)
MU   50.80 (+0.18%)
TSLA   1,688.56 (+9.32%)
AMD   56.49 (+1.09%)
T   29.95 (-0.60%)
DIS   119.75 (+0.34%)
NFLX   560.78 (+2.20%)
BAC   24.21 (+0.79%)
AAPL   395.61 (+3.11%)
MSFT   214.48 (+0.38%)
FB   247.24 (+0.89%)
GOOGL   1,562.67 (+1.54%)
AMZN   3,274.31 (+2.32%)
NVDA   421.63 (+0.59%)
CGC   17.99 (+3.27%)
MU   50.80 (+0.18%)
TSLA   1,688.56 (+9.32%)
AMD   56.49 (+1.09%)
T   29.95 (-0.60%)
DIS   119.75 (+0.34%)
NFLX   560.78 (+2.20%)
BAC   24.21 (+0.79%)
AAPL   395.61 (+3.11%)
MSFT   214.48 (+0.38%)
FB   247.24 (+0.89%)
GOOGL   1,562.67 (+1.54%)
AMZN   3,274.31 (+2.32%)
NVDA   421.63 (+0.59%)
CGC   17.99 (+3.27%)
MU   50.80 (+0.18%)
TSLA   1,688.56 (+9.32%)
AMD   56.49 (+1.09%)
T   29.95 (-0.60%)
DIS   119.75 (+0.34%)
NFLX   560.78 (+2.20%)
BAC   24.21 (+0.79%)
AAPL   395.61 (+3.11%)
MSFT   214.48 (+0.38%)
FB   247.24 (+0.89%)
GOOGL   1,562.67 (+1.54%)
AMZN   3,274.31 (+2.32%)
NVDA   421.63 (+0.59%)
CGC   17.99 (+3.27%)
MU   50.80 (+0.18%)
TSLA   1,688.56 (+9.32%)
AMD   56.49 (+1.09%)
T   29.95 (-0.60%)
DIS   119.75 (+0.34%)
NFLX   560.78 (+2.20%)
BAC   24.21 (+0.79%)
Log in

NASDAQ:CKPTCheckpoint Therapeutics Stock Price, Forecast & News

$1.74
-0.03 (-1.69 %)
(As of 07/13/2020 01:21 PM ET)
Add
Compare
Today's Range
$1.71
Now: $1.74
$1.79
50-Day Range
$1.77
MA: $2.07
$2.27
52-Week Range
$1.05
Now: $1.74
$3.34
Volume3,214 shs
Average Volume275,076 shs
Market Capitalization$95.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the anti-PD-L1 antibodies anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More
Checkpoint Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.71 million
Book Value$0.34 per share

Profitability

Net Income$-24,710,000.00
Net Margins-949.53%

Miscellaneous

Employees7
Market Cap$95.80 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

How has Checkpoint Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Checkpoint Therapeutics' stock was trading at $1.33 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CKPT shares have increased by 30.8% and is now trading at $1.74. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Checkpoint Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Checkpoint Therapeutics.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Checkpoint Therapeutics.

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.06) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The company had revenue of $0.97 million for the quarter, compared to analyst estimates of $0.43 million. Checkpoint Therapeutics had a negative return on equity of 182.15% and a negative net margin of 949.53%. View Checkpoint Therapeutics' earnings history.

What price target have analysts set for CKPT?

2 brokers have issued 1-year price targets for Checkpoint Therapeutics' shares. Their forecasts range from $8.00 to $15.00. On average, they expect Checkpoint Therapeutics' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 560.9% from the stock's current price. View analysts' price targets for Checkpoint Therapeutics.

Has Checkpoint Therapeutics been receiving favorable news coverage?

Press coverage about CKPT stock has been trending very negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Checkpoint Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Checkpoint Therapeutics.

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the following people:
  • Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $1.74.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $95.80 million and generates $1.71 million in revenue each year. The company earns $-24,710,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is www.checkpointtx.com.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.